| [1] |
Wiley SR, Schooley K, Smith CA, et al.Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity, 1995, 3(6) : 673-682.
|
| [2] |
Sheikh MS, Huang Y.Death receptors as targets of cancer therapeutics[J]. Curr Cancer Drug Targets, 2004, 4(1): 97-104.
|
| [3] |
Nagane M, Huang HJ, Cavenee WK.The potential of TRAIL for cancer chemotherapy[J]. Apoptosis, 2001, 6(3): 191-197.
|
| [4] |
Almasan A, Ashkenazi A.Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer[J]. Cytokine Growth Factor Rev,2003,14(3/4):337-348.
|
| [5] |
章越, 沈亚领, 夏小霞, 等. 可溶性TRAIL蛋白的高密度培养及补料策略研究[J]. 生物工程学报, 2004,20(3):408-413.
|
| [6] |
Beranova L,Pombinho AR,Spegarova J,et al.The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms[J]. Apoptosis, 2013, 18(6):739-750.
|
| [7] |
Hague A,Hicks DJ,Macfarlane M,et al.Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis[J]. Br J Cancer, 2005, 92(4): 736-742.
|
| [8] |
Volkmann X, Fischer U, Bahr MJ, et al.Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver[J]. Hepatology, 2007, 46(5):1498-1508.
|
| [9] |
Hao Z, Mak TW.Type I and type II pathways of Fas-mediated apoptosis are differentially controlled by XIAP[J]. J Mol Cell Biol, 2010, 2(2):63-64.
|
| [10] |
Wan Houdt UJ, HavivYS, Lu B, et a1. The human Survivin promoter: a novel transcriptional targeting strategy for treatment of glioma[J]. Neurosurg, 2006,104(4): 583-592.
|
| [11] |
Strasser A, Jost PJ, Nagata S.The many roles of FAS receptor signaling in the immune system[J]. Immunity, 2009, 30(2):180-192.
|
| [12] |
Pei Z, Chu L, Zou W, et al.An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice[J]. Hepatology, 2004, 39(5):1371-1381.
|
| [13] |
Ma H, Liu Y, Liu S, et al.Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors[J]. Int J Cancer, 2005, 116(2): 314-321.
|
| [14] |
Shi J, Zheng DX, Xu RA, et al.TRAIL: A potential agent for cancer therapy[J]. Curr Mol Med, 2003, 3: 727-736.
|
| [15] |
Wu GS.TRAIL as a target in anti-cancer therapy[J]. Cancer Lett, 2009, 285(1): 1-5.
|
| [16] |
Shankar S, Srivastava RK.Enhancement of therapeutic potential of trail by cancer chemotherapy and irradiation: mechanisms and clinical implications[J]. Drug Resist Updat, 2004, 7(2):139-156.
|
| [17] |
Kisim A, Atmaca H, Cakar B, et al.Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels[J]. J Cancer Res Clin Oncol,2012,138(7):1155-1163.
|
| [18] |
Ding J, Polier G, Kohler R, et al.Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression[J]. J Biol Chem,2012,287(1):641-649.
|
